Electronic reproduction. Ann Arbor, MI Available via World Wide Web.
Cover -- Medical Innovation and Disease Burden -- Title -- Copyright -- Contents -- Tables -- Figures -- Acknowledgements -- Abbreviations -- Introduction -- Medical innovations and public health priorities -- Health R&D in India -- Public health relevance of medical R&D -- 1 Medical Innovation and Its Institutional Co-production in India -- The Indian pharmaceutical industry: sales, export and R&D -- Performance of the biopharmaceutical industry in India -- The Indian medical device/technology sector -- The institutional network of medical innovation
State, academia and industry linkages in India -- Funding agencies and priority areas in medical innovation -- Partnering institutions for clinical trials -- Conclusion -- Appendix 1A -- 2 The Disease Focus of Health Research and Development -- R&D and disease focus -- Disease focus of R&D in branded generics and biosimilars -- Disease focus of therapeutic and vaccine R&D of biopharmaceuticals in India -- R&D pipeline of major India biopharmaceuticals -- Disease focus of new chemical entity research in India -- Disease focus of medical device/technology R&D in India -- Conclusion -- Appendix 2A
Brief webnography of selected biopharmaceutical companies -- 3 Drug Development and Responsiveness to Disease Burden -- Causes of deaths in India: a detailed analysis -- Disease-specific mortality -- Morbidity burden of diseases -- Responsiveness of therapeutic drug development to disease burden -- Implications of lower focus on infectious diseases -- Responsiveness of vaccine development to the infectious disease burden -- Conclusion -- 4 Affordability and the Social Divide -- Drug price (de)regulation in India -- The financial burden and affordability of medicines in India
Price variations of branded drugs -- Price regulation and drug development: ongoing debates -- Value-based pricing and the debate on price reduction in India -- Technological innovation and cost of drugs -- The social divide -- Medicalisation, pharmaceuticalisation and social inequality -- Conclusion -- 5 The Puzzle of Responsive and Responsible Medical Innovation -- Challenges of responsive medical innovation -- Actors, priorities and equity issues -- Policy mismatches -- Responsive and responsible innovation: the way ahead -- Regulation with facilitation -- Balancing the power in global R&D